FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 20:56:35 28/06/2024 BST | ||
| 8.52 EUR | -4.05% |
|
| 1 month | +18.66% | ||
| 3 months | +43.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 8.52 | -4.05% |
| 27/06/24 | 8.88 | +0.11% |
| 26/06/24 | 8.87 | -0.22% |
| 25/06/24 | 8.89 | -0.89% |
| 24/06/24 | 8.97 | +5.28% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 08:56 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MC4JT8 |
| ISIN | DE000MC4JT83 |
| Date issued | 17/10/2019 |
| Strike | 354.5 $ |
| Maturity | Unlimited |
| Parity | 12.6 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 38.05 € |
|---|---|
| Lowest since issue | 0.76 € |
| Spread | 0.04 € |
| Spread % | 0.47% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Certificates
- Certificat
